Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B3bc87ed208aba1b03b6bb95cdfd1cbf5> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B3bc87ed208aba1b03b6bb95cdfd1cbf5 NCIT_P378 "NCI" @default.
- B3bc87ed208aba1b03b6bb95cdfd1cbf5 type Axiom @default.
- B3bc87ed208aba1b03b6bb95cdfd1cbf5 annotatedProperty IAO_0000115 @default.
- B3bc87ed208aba1b03b6bb95cdfd1cbf5 annotatedSource NCIT_C150377 @default.
- B3bc87ed208aba1b03b6bb95cdfd1cbf5 annotatedTarget "Autologous T-lymphocytes that have been transduced, via a proprietary technology involving a recombinant human fibronectin fragment to enhance transduction efficiency, with a retroviral vector to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19 coupled to co-stimulatory molecules, with potential immunostimulating and antineoplastic activities. Upon transfusion, anti-CD19-CAR-expressing autologous T-lymphocytes TBI-1501 target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, the release of cytotoxic molecules and the induction of tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. Incorporation of the costimulatory signaling domains increase proliferation and activation of T-cells." @default.